New Mexico Register / Volume XXX, Issue
23 / December 17, 2019
This is an amendment to
16.2.18 NMAC, Sections 13 and 25, effective 1/4/2020.
16.2.18.13 BASIC INJECTION THERAPY EDUCATIONAL
COURSE HOURS: The education offered shall consist of a minimum total of 58
contact hours with at least the minimum number of hours of education in the
areas listed below:
A. eight hours in pharmacology and
biomedical differential diagnosis relative to the prescription, administration,
compounding and dispensing of the authorized substances in the basic injection
therapy formulary including homeopathic medicines;
B. two hours in the drawing and
compounding of the authorized substances intended for injection in compliance
with USP 797, utilizing approved aseptic technique and proper record keeping [and]
for storage and dispensing of substances; at least half of the
required hours shall be clinical practice;
C. 14 hours in orthopedic and
neurological evaluation; at least half of these required hours shall be
clinical practice;
D. two hours in the theory and practice
of vapocoolant spray and stretch techniques using the
authorized vapocoolants; at least half of these
required hours shall be clinical practice;
E. 28 hours in the theory and practice
of injection therapy including: 11 hours of trigger point therapy and injection
of acupuncture points; 11 hours of basic mesotherapy;
six hours of basic neural therapy, and therapeutic injections (vitamins), using
the authorized substances in the basic injection therapy formulary; at least
half of these required hours shall be clinical practice;
F. one hour in pharmaceutical law as
provided by the New Mexico board of pharmacy;
G. one in oriental medicine scope of
practice relative to the authorized substances and techniques; and
H. a minimum of two hours in the use of
inhaled oxygen O2 and IM epinephrine for emergency use.
[16.2.18.13 NMAC - Rp, 16.2.18.12 NMAC, 6/16/2015; A, 1/4/2020]
16.2.18.25 BIOIDENTICAL HORMONE THERAPY
EDUCATIONAL COURSE HOURS: The
bioidentical hormone educational course shall consist of a minimum total of 80
hours of education, with at least [twenty four (24)] 27 hours of
practical experience defined in [Subsections B, C, D, E, and F of 16.2.18.26
NMAC in the areas listed] Subsections B, C, D, E, and F below:
A. eight hours in the pharmacology of
bioidentical hormones;
B. 18 hours in an overview of the
endocrine system, including the anatomy and interactive physiology of the
hypothalamic-pituitary-adrenal-thyroid (HPAT) and gonadal axis, the stress
response and normal adrenal and thyroid function; also to include normal male
and female sex hormone physiology; at least half of these hours shall be in
practice or review of case studies;
C. 20 hours in theory and practice of
endocrinology including evaluation and treatment of the patient with hormonal
dysfunction and imbalances including but not limited to; adrenal fatigue,
auto-immune endocrine disorders, hypothyroid, hyperthyroid, men’s hormone
imbalances and women’s hormonal imbalances pre, peri
and post menopause and consideration and assessment for treatment with
bio-identical hormone replacement therapy, BHRT; at least half of these hours
will be in practice or review of case studies;
D. 14 hours in blood chemistry analysis
including but not limited to; CBC, CMP, LFT, lipids, ferritin, homocysteine,
vitamin D, iodine, hs CRP, fibrinogen, ANA, ESR, HgBAIC, insulin antibodies;
E. two hours in urine analysis;
F. 16 hours in the assessment and
treatment of hormone and neurotransmitter imbalances through blood, urine and
saliva hormone testing and evaluation; appropriate treatment options for the
biomedical differential diagnoses including, but not limited to; adrenal
fatigue, thyroid imbalances, andropause, menopausal
syndrome, and other male and female hormone imbalances; at least half of these
hours shall be in practice or case study review;
G. one hour in pharmaceutical law as
provided by the New Mexico board of pharmacy; and
H. one hour in oriental medicine scope
of practice relative to the prescription or administration of the authorized
substances.
[16.2.18.25 NMAC - Rp, 16.2.18.20 NMAC, 6/16/2015; A, 1/4/2020]